Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventrus Reports Positive Phase III, But Warns Again That FDA May Want Second Study

This article was originally published in The Pink Sheet Daily

Executive Summary

After announcing positive results from a Phase III European study of topical diltiazem for anal fissures, Ventrus cautions that a new study including Americans may be needed for FDA approval. The company says that if it gains approval, it may price the therapy on a par with recently cleared Rectiv from ProLactan.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel